自从1976年Morgan首次发现白细胞介素-2以来,人们逐渐认识到它在机体特异性免疫应答中的重要地位,并于80年代中期用于癌症过继免疫疗法,迄今几年中已经取得了很大进展,现将白细胞介素-2(IL—2)过继免疫疗法有关问题的进展综述如下:1 IL—2过继免疫疗法应用的基础IL—2最初被命名为T细胞生长因子(TCGF),直到1979年才正式定名为IL—2。在10多年的研究中发现,IL—2系由激活的T淋巴细胞分泌的一种分子量为15.6KD Since Morgan first discovered interleukin-2 in 1976, people have gradually realized its important role in the body-specific immune response, and in the mid-1980s used for cancer adoptive immunotherapy, has made great progress in recent years. Progressively, the progress of the issues related to adoptive immunotherapy of interleukin-2 (IL-2) is summarized as follows: 1 The basic IL-2 used in the application of IL-2 adoptive immunotherapy was originally named T cell growth factor (TCGF) until In 1979 it was officially named IL-2. In more than 10 years of research, it has been found that IL-2 is secreted by activated T lymphocytes with a molecular mass of 15.6 KD.